How much cash does Seres have left and when might it need to raise more?

As of March 31, 2026, Seres reported $29.8M in cash against roughly $19.9M in quarterly net losses — implying a very limited runway. Investors should watch for any equity offering, convertible note, or partnership financing announcement in the coming quarters.

What is SER-155 and why does it matter for the stock?

SER-155 is Seres' lead pipeline candidate targeting prevention of immune-checkpoint-inhibitor-related enterocolitis, a serious complication in cancer patients on immunotherapy. A positive clinical readout or partnership deal for SER-155 could be a major upside catalyst given the company's otherwise thin revenue base.

For leverage traders, how volatile can MCRB get around clinical catalysts?

Micro-cap clinical-stage biotech stocks like MCRB routinely move 20–50% on binary data events or financing announcements. High leverage amplifies both directions sharply, so position sizing relative to account equity is critical when holding through catalyst windows.

Does this miss affect the broader biotech ETF or sector?

The impact on diversified biotech benchmarks is minimal given MCRB's small market cap. However, peers with similar cash-burn profiles and limited commercial revenue may see marginal sympathy pressure if the miss raises broader concerns about micro-cap biotech funding conditions.

Enlaces Rápidos

Seres Therapeutics (MCRB) Q3 2026 Miss: EPS -$1.63 and Revenue of $0.59M Both Fall Far Short

Publicado: 2026-11-04 13:00:28 UTC

Instantánea de Datos

Q3 2026 Revenue

$0.59M (missed by $5.76M)

After-Hours Move

~-11%

Q1 2026 Net Loss

$19.9M

Q3 2026 GAAP EPS

-$1.63 (missed by $0.63)

Cash (Mar 31, 2026)

$29.8M

Puntos Clave

•MCRB Q3 2026 GAAP EPS of -$1.63 missed by $0.63; revenue of $0.59M missed by $5.76M — both material shortfalls.
•Shares fell ~11% in after-hours trading on November 4, 2026, confirming an immediate negative market reaction.
•Cash of $29.8M (as of March 31, 2026) against ~$19.9M quarterly net losses signals tight runway and elevated dilution risk.
•SER-155 pipeline progress for irEC is the key upside catalyst; the stock is best viewed as a binary clinical-event instrument.
•Broader sector and index impact is minimal — this is a company-specific, micro-cap biotech event.

The leverage map uses the State Street SPDR S&P Biotech ETF (XBI) as its primary asset, rather than Seres Therapeutics (MCRB). Across seven candles, XBI opened at 153.815, reached a high of 156.89 and a low of 153.385, and closed at 154.835, up 0.66% over 24 hours. The map shows a short position entered at 154.835, with leverage tiers of 100×, 500×, and 2,000×. Liquidation prices are not provided in the chart data. The accompanying pulse headline reports that Seres Therapeutics’ Q3 2026 results missed expectations: EPS was -$1.63 and revenue was $0.59 million. Those figures describe MCRB’s reported results, while the plotted price action and leverage entry refer to XBI; the chart does not provide MCRB’s price change or a direct comparison between the two securities. — XBI closed at 154.835, up 0.66% in 24 hours; the leverage map marks a short entry at 154.835, while the headline reports MCRB Q3 2026 EPS of -$1.63 and revenue of $0.59M.

As reported by Seeking Alpha, Seres Therapeutics posted a Q3 2026 GAAP EPS loss of -$1.63, missing consensus by $0.63, while revenue came in at just $0.59 million — a staggering $5.76 million below ex

Event Analysis

As reported by Seeking Alpha, Seres Therapeutics posted a Q3 2026 GAAP EPS loss of -$1.63, missing consensus by $0.63, while revenue came in at just $0.59 million — a staggering $5.76 million below expectations. The results were released on November 4, 2026, triggering an approximately 11% decline in after-hours trading. Despite a reported 68.6% year-over-year revenue gain, the absolute figure remains negligible for a clinical-stage company, underscoring just how pre-commercial Seres truly is.

Seres is a development-stage live-biotherapeutics company that pivoted sharply after divesting its VOWST business earlier in 2026, which generated a one-time $25 million gain that flattered prior-quarter headline numbers. Stripped of that event, the company's core operating profile is one of persistent losses and minimal revenue. As of March 31, 2026, the company held $29.8 million in cash while burning through approximately $19.9 million in net losses per quarter — a runway calculation that investors will scrutinize closely. This miss amplifies already meaningful financing risk.

The one counterweight is pipeline optionality. Alongside the results, Seres announced plans to advance SER-155 for the prevention of immune-checkpoint-inhibitor-related enterocolitis (irEC) — a niche but high-unmet-need indication within oncology supportive care. For a company this size, a single successful trial readout or partnership deal can be transformative, but it also means the stock is effectively a binary event instrument rather than a traditional earnings story. The miss narrows the margin for clinical-execution error.

This event fits within the broader biotech drug pipeline catalysts framework, where development-stage companies trade on probability-adjusted pipeline value rather than current financials. For micro-cap names like MCRB, wide earnings misses matter less as accounting events and more as signals about cash discipline and strategic momentum.

What This Means for Traders

The immediate market signal is bearish for MCRB shares. The dual miss on both EPS and revenue, combined with an 11% after-hours drop, sets a negative tone for the next session. Because this news broke after regular NYSE hours, traders on CoinUnited.io with access to MCRB stock CFDs can position ahead of the standard open rather than waiting for the next session's price discovery. The key near-term risk variables are dilution (equity or convertible issuance to extend runway) and whether Q4 guidance or SER-155 milestones can partially re-anchor sentiment.

Beyond MCRB itself, the event's read-across to the broader biotech sector is limited but worth monitoring for other micro-cap clinical-stage peers with similar cash-burn profiles. As the Q3 earnings miss playbook outlines, the sharpest moves in small-cap biotech often come not from the miss itself but from follow-on financing announcements or clinical updates that arrive within days. Watch for any 8-K filings from Seres in the coming weeks.

Volatility should remain elevated near-term given the binary nature of the pipeline and the tight cash position. Leverage should be sized cautiously — this stock can move 20–40% on a single data or financing headline.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.

Preguntas Frecuentes

The 68.6% growth sounds impressive but is misleading at this scale — going from ~$0.35M to ~$0.59M is immaterial for a company with this cost base. What moved the stock was the $5.76M miss versus consensus, which signals the company is not commercializing as fast as expected.